Regeneron Pharmaceuticals (REGN) Long-Term Investments (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Long-Term Investments of $9.8 billion for Q2 2026, down 2.29% year-over-year from $10.1 billion in Q2 2025, and little changed quarter-over-quarter from $9.8 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Long-Term Investments (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Long-Term Investments history runs 18 years deep, the most recent figure standing at $9.8 billion for Q2 2026.
- In Q2 2026, Long-Term Investments fell 2.29% year-over-year to $9.8 billion; the TTM figure through Jun 2026 stood at $9.8 billion (down 2.29% YoY), while the FY2025 annual figure was $10.3 billion, up 15.29% from the prior year.
- Long-Term Investments for Q2 2026 stood at $9.8 billion, roughly flat from $9.8 billion in the prior quarter.
- The five-year high for Long-Term Investments was $10.3 billion in Q3 2025, with the low at $5.4 billion in Q4 2023.
- The 5-year median for Long-Term Investments is $7.4 billion (2022), against an average of $7.8 billion.
- The sharpest annual moves came in 2022 and 2023: Long-Term Investments soared 99.9% in 2022, then fell 18.13% in 2023.
- Regeneron Pharmaceuticals' Long-Term Investments stood at $6.6 billion in 2022, then fell by 18.13% to $5.4 billion in 2023, then surged by 64.92% to $8.9 billion in 2024, then rose by 15.29% to $10.3 billion in 2025, then slipped by 4.21% to $9.8 billion in 2026.
- Business Quant data shows REGN's Long-Term Investments at $9.8 billion in Q2 2026, $9.8 billion in Q1 2026, and $10.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.83 Bn |
| Mar 31, 2026 | 9.79 Bn |
| Dec 31, 2025 | 10.26 Bn |
| Sep 30, 2025 | 10.29 Bn |
| Jun 30, 2025 | 10.06 Bn |
| Mar 31, 2025 | 9.28 Bn |
| Dec 31, 2024 | 8.90 Bn |
| Sep 30, 2024 | 8.49 Bn |
| Jun 30, 2024 | 7.72 Bn |
| Mar 31, 2024 | 6.98 Bn |
| Dec 31, 2023 | 5.40 Bn |
| Sep 30, 2023 | 5.78 Bn |
| Jun 30, 2023 | 6.33 Bn |
| Mar 31, 2023 | 6.07 Bn |
| Dec 31, 2022 | 6.59 Bn |
| Sep 30, 2022 | 5.97 Bn |
| Jun 30, 2022 | 6.42 Bn |
| Mar 31, 2022 | 7.08 Bn |
| Dec 31, 2021 | 6.84 Bn |
| Sep 30, 2021 | 5.63 Bn |